-
Funding to accelerate development and commercialization of company’s breakthrough blepharoplasty surgery device
-
John Garland has been appointed as Chief Commercial Officer
BEND, Ore., July 23, 2024–(BUSINESS WIRE)–Oseru, a medical device company specializing in innovative solutions for skin surgery led by Dr. Knute and Patricia Buehler, today announced the successful completion of a $4.7 million funding round to accelerate the development and commercialization of their groundbreaking Ziplyft blepharoplasty surgery device. The round was led by individuals and family offices, including investment from Nike co-founder Phil Knight. Additional investors include Oregon ToughTech BreakThrough Fund managed by ONAMI for Business Oregon and SOPHINCAP, the Corporate Venture Fund of Laboratorios Sophia, an international ophthalmology company and leader in research and innovation. The resulting oversubscribed funding round reflects investors’ strong confidence in Osheru’s transformative approach to blepharoplasty.
“This $4.7 million in funding marks a pivotal moment for Osheru,” said Dr. Patricia Buehler, CEO. “It demonstrates the strong confidence in Ziplyft from both the medical community and investors, validating our vision to revolutionize blepharoplasty with cutting-edge technology.”
Osheru also announced the appointment of John Garland as Chief Commercial Officer. A veteran executive in the ophthalmology industry, Mr. Garland brings decades of experience in medical device innovation and commercialization, having managed global operations in 70 countries with outstanding results. His strategic leadership and passion for improving the surgeon and patient experience will be instrumental as Osheru accelerates its commercialization efforts.
“Joining Osheru to launch Ziplyft is an exciting opportunity,” said Mr. Garland. “This innovative technology addresses key challenges in blepharoplasty, promising improved outcomes for patients and enhanced capabilities for surgeons. I look forward to furthering its development and advancing the field of blepharoplasty.”
According to the International Society of Aesthetic Plastic Surgery (ISAPS), an estimated 1.7 million blepharoplasty procedures were performed worldwide in 2023, representing a 24 percent increase compared to 2022. Blepharoplasty, a procedure aimed at rejuvenating the appearance of the eyelids, remains one of the most sought-after cosmetic procedures in the US, especially with the rise of video calls and selfies. Traditional methods, unchanged for decades, have fueled demand for safer, less invasive alternatives like Ziplyft, placing Osheru at the forefront of surgical innovation in this space.
